comparemela.com

Latest Breaking News On - Altimmune - Page 1 : comparemela.com

Altimmune (NASDAQ:ALT) Cut to "Neutral" at Guggenheim

Guggenheim downgraded shares of Altimmune (NASDAQ:ALT – Free Report) from a buy rating to a neutral rating in a research note released on Monday, Marketbeat reports. Several other analysts have also commented on the stock. B. Riley reaffirmed a buy rating and issued a $20.00 price objective on shares of Altimmune in a research report […]

Investment-advisers
Miracle-mile-advisors
Altimmune-inc
Star-investment-management-corp
Wealthplan-investment-management
Goldman-sachs-group
Free-report
Get-free-report
Plan-investment-management
Star-investment-management
Altimmune-daily

Altimmune (NASDAQ:ALT) Shares Up 6.5%

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) shot up 6.5% during trading on Monday . The stock traded as high as $7.37 and last traded at $7.36. 1,032,095 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 5,444,214 shares. The stock had previously closed at $6.91. Analyst Upgrades […]

Altimmune-company-profile
Miracle-mile-advisors
Goldman-sachs-group
Nasdaq
Altimmune-inc
Investment-advisers
Wealthplan-investment-management
Get-free-report
Plan-investment-management
Morrison-wealth-management
Altimmune-daily

Altimmune (NASDAQ:ALT) Given New $12.00 Price Target at HC Wainwright

Altimmune (NASDAQ:ALT – Free Report) had its price target reduced by HC Wainwright from $15.00 to $12.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the stock. ALT has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on shares […]

Nasdaq
Altimmune-inc
Marshall-wace
Vanguard-group-inc
Nuveen-asset-management
Blackrock-inc
Goldman-sachs-group
Free-report
Trading-down
Asset-management
Street-corp

vimarsana © 2020. All Rights Reserved.